Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ankyrin repeat domain 18E, pseudogene (ANKRD18EP) is a human pseudogene, meaning it is a segment of DNA that resembles a functional gene but has lost its protein-coding ability and is not known to produce a functional protein[6][5][11]. Pseudogenes like ANKRD18EP may be transcribed into RNA but typically do not have direct therapeutic, biochemical, or physiological roles as targets for drugs or biomarker monitoring[2]. There is no evidence that ANKRD18EP functions as a receptor, enzyme, transporter, or transcription factor, nor are there any known drug or disease associations specific to this pseudogene[6][11]. Its scientific classification and biological role are primarily as a processed pseudogene, with no established disease relevance or therapeutic targeting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin repeat domain 18E, pseudogene (ANKRD18EP).